Blog
RSS FeedPosted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory ...
Posted by Michael Wonder on 17 Jan 2019
NICE approval for Verzenios in metastatic breast cancer
17 January 2019 - NICE has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...
Posted by Michael Wonder on 10 Jan 2019
New migraine drug not cost-effective NICE says in draft guidance
10 January 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of ...
Posted by Michael Wonder on 09 Jan 2019
NICE publishes final guidance on the use of darvadstrocel on the NHS
9 January 2019 - The Department of Health and Social Care has asked the NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Jan 2019
Stivarga final NICE recommendation for hepatocellular carcinoma
9 January 2019 - Bayer’s Stivarga has received a final green light from NICE for use by the NHS to ...
Posted by Michael Wonder on 04 Jan 2019
Third biological treatment gives more choice for people with severe asthma
4 January 2019 - Another potentially life-changing treatment should be available to people with a severe form of asthma, NICE says. ...
Posted by Michael Wonder on 21 Dec 2018
NICE recommends Lenvima for advanced liver cancer
21 December 2018 - NICE has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma ...
Posted by Michael Wonder on 19 Dec 2018
NICE authorises MSD's Keytruda for stage III melanoma
19 December 2018 - MSD’s Keytruda has been given a green light for use within the EU as an adjuvant ...
Posted by Michael Wonder on 12 Dec 2018
NICE says no to rival Alnylam and Akcea amyloidosis drugs – but deal could be done
12 December 2018 - Room for manoeuvre after initial rejection. ...
Posted by Michael Wonder on 07 Dec 2018
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
7 December 2018 - Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma. ...
Posted by Michael Wonder on 04 Dec 2018
NICE backs Cimzia for psoriasis, but rejects Ilumetri
4 December 2018 - Cost watchdog NICE has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but ...
Posted by Michael Wonder on 30 Nov 2018
NICE U turn on Opdivo for skin cancer recurrence
30 November 2018 - NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence ...
Posted by Michael Wonder on 29 Nov 2018
Life extending treatment for patients with advanced liver cancer recommended by NICE
29 November 2018 - Approving regorafenib is a "welcome step forward" for those people who are eligible. ...
Posted by Michael Wonder on 28 Nov 2018
NICE publishes FAD for new indication for Xeljanz
28 November 2018 - NICE has published a final appraisal document for tofacitinib citrate for the treatment of patients with ...